US Stock MarketDetailed Quotes
IRON Disc Medicine
- 49.410
- +0.660+1.35%
Close Aug 23 16:00 ET
- 49.410
- 0.0000.00%
Post 19:18 ET
1.47BMarket Cap-13649P/E (TTM)
50.170High48.450Low178.64KVolume49.300Open48.750Pre Close8.84MTurnover1.16%Turnover RatioLossP/E (Static)29.73MShares77.60052wk High3.00P/B758.59MFloat Cap25.60052wk Low--Dividend TTM15.35MShs Float190.850Historical High--Div YieldTTM3.53%Amplitude11.600Historical Low49.461Avg Price1Lot Size
Disc Medicine Stock Forum
Sign in to post a comment
🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
14
3
$Disc Medicine (IRON.US)$ easy money
2
$Cellectar BioSciences (CLRB.US)$ Phase 2
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2 ...
$Regenxbio (RGNX.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals (EYPT.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Disc Medicine (IRON.US)$ Phase 2
$Atea Pharmaceuticals (AVIR.US)$ Phase 2
$Allakos (ALLK.US)$ Phase 2 ...
37
6
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Following a turbulent period, there has been a notable change in the trajectory of biotech stocks. After experiencing significant downturns in 2021 and 2022, the $SPDR S&P Biotech ETF (XBI.US)$ has seen an increase of 5.5% in the current year. However, it continues to trail considerably behind the $S&P 500 Index (.SPX.US)$, which has achieved a 24% gain. However, analysts indicate that the previously cool sent...
29
1
$Auddia (AUUD.US)$ $Charles River (CRL.US)$ $Devon Energy (DVN.US)$ $Eastside Distilling (EAST.US)$ $Finch Therapeutics (FNCH.US)$ $Forza X1 (FRZA.US)$ $iBio Inc (IBIO.US)$ $Disc Medicine (IRON.US)$ $Leju Holdings (LEJU.US)$ $Lumen Technologies (LUMN.US)$ $MediaCo (MDIA.US)$ $The OLB Group (OLB.US)$ $Oracle (ORCL.US)$ $Rockwell Medical (RMTI.US)$ $Target (TGT.US)$
$ArcBest (ARCB.US)$ initiated at buy by Jefferies, announced target price at $110.00.
$Saia (SAIA.US)$ initiated at buy by Jefferies, announced targe price at $350.00.
$AutoZone (AZO.US)$ was upgraded by Evercore ISI Group from in-line to outperform, increased target price to $2700.00.
$Oracle (ORCL.US)$ was upgraded by Wolfe Research from peer perform to outperform, increased target price to $130.00.
$BILL Holdings (BILL.US)$ was downg...
$Saia (SAIA.US)$ initiated at buy by Jefferies, announced targe price at $350.00.
$AutoZone (AZO.US)$ was upgraded by Evercore ISI Group from in-line to outperform, increased target price to $2700.00.
$Oracle (ORCL.US)$ was upgraded by Wolfe Research from peer perform to outperform, increased target price to $130.00.
$BILL Holdings (BILL.US)$ was downg...
16
$Disc Medicine (IRON.US)$ no attention very recent rs and it flies
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
The Real Wojak : Do you have like a top 3-5 that you like more than all the other ones? This list is way too long
72991267 : Glad I have some $Candel Therapeutics (CADL.US)$ after my disastrous SBFM.
Rana Hasan1 : List too long